equitieswatch
Tuesday, February 7, 2023
About us
Advertise
  • Home
  • Stock Market
  • Finance
  • Cryptocurrency
  • Commodities
No Result
View All Result
Equitieswatch.com
No Result
View All Result

Chinese Omicron-specific mRNA COVID vaccine candidate to be trialed in UAE By Reuters

by equitieswatch
April 30, 2022
in Stock Market

YOU MAY ALSO LIKE

Mexico’s new airport gets boost from Panama’s Copa Airlines By Reuters

Honda and Sony Team Up to Tackle Tesla


© Reuters. FILE PHOTO: The words “OMICRON SARS-COV-2” are seen reflected in a drop from a syringe needle in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration

BEIJING (Reuters) – China’s Suzhou Abogen Biosciences Co said its COVID-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates.

With Friday’s announcement, Abogen joins Pfizer/BioNTech and Moderna (NASDAQ:) in trialing candidates modified specifically against Omicron, a highly transmissible variant with increased resistance to antibodies elicited by existing shots.

Mainland China has vaccinated over 88% of its 1.4 billion people against COVID with non-mRNA shots. It has not approved any foreign vaccines, although real-world data indicated the two most used Chinese products, manufactured by Sinopharm and Sinovac, have lower effectiveness against COVID infection than mRNA shots from Pfizer/BioNTech and Moderna.

Besides the UAE, Abogen was communicating with regulators in China and other countries on potential clinical trials for the Omicron-specific candidate, it said in a statement.

An mRNA candidate based on an older coronavirus strain without major mutations, which Abogen co-developed with Walvax Biotechnology and a Chinese military-backed research institution, is being tested in a Phase III trial in China, Mexico and Indonesia.

Walvax is also partnering with Shanghai-based startup RNACure to develop a variants-targeting mRNA vaccine candidate, with design different from Abogen’s.

Two Omicron-specific vaccine candidates from Sinopharm and one from Sinovac, containing inactivated or “killed” coronavirus, have been cleared for clinical trials in Hong Kong and mainland China.

The UAE regulator has approved clinical trials for a third Omicron-specific candidate from Sinopharm, based on protein, as well as for the firm’s two inactivated Omicron-specific candidates, Sinopharm subsidiary China National Biotec Group said on Friday.

Source link

ShareTweetPin

Search

No Result
View All Result

Recent News

Oil slips further on demand, financial market worries By Reuters

Oil Sinks Further Amid China Concerns, Weakened Economic Prospects By Investing.com

October 25, 2022
Gold Up, Set for Second Weekly Gain as Dollar Falls from 20-Year High By Investing.com

Gold Pressured Near $1,650, Copper Muted on Economic Fears By Investing.com

October 25, 2022
Explainer-What would be the impact of Russian oil sanctions in Europe? By Reuters

Oil prices edge higher as U.S. dollar eases By Reuters

October 25, 2022
Equitieswatch.com

Equitieswatch.com is your Stock Market, Finance, Forex, Cryptocurrency, Business, NFT News Website. We provide you with the latest breaking news and videos straight from the Business industry.

  • Home
  • About us
  • Contact
  • Privacy Policy

© 2022 www.equitieswatch.com

No Result
View All Result
  • Home
  • Stock Market
  • Finance
  • Cryptocurrency
  • Commodities

© 2022 www.equitieswatch.com